Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P, Gu W, Nilsson K, Knowles D M, Boccadoro M
Department of Pathology, College of Physicians and Surgeons, Columbia University, NY.
Leukemia. 1994 May;8(5):758-67.
The role of loss or inactivation of the retinoblastoma (Rb1) and p53 tumor suppressor genes in the pathogenesis of various human malignancies has been well established, yet little is known regarding plasma cell dyscrasias. In the present study, the loss of Rb1 protein expression, and the presence of Rb1 gene rearrangements as well as the presence of p53 somatic mutations (exons 5 through 9) were investigated in a panel of plasma cell dyscrasias, including 15 monoclonal gammopathies of undetermined significance (MGUS), 63 multiple myelomas (MM), and 18 plasma cell leukemias (PCL). In the same panel of cases, we established the frequency of ras oncogene mutations, the main genetic lesion associated with MM. We report that loss of Rb1 protein and p53 mutations are detectable in 34.7 and 9.8% of MM and PCL primary cases; no lesion was found in MGUS. In advanced stage MM, and PCL cases, Rb1 and p53 inactivation, as well as ras mutations were detected. Our findings show that Rb1 and p53 inactivation are associated with aggressive plasma cell dyscrasias, suggesting a role for these lesions in tumor progression rather than initiation.
视网膜母细胞瘤(Rb1)和p53肿瘤抑制基因的缺失或失活在各种人类恶性肿瘤发病机制中的作用已得到充分证实,但关于浆细胞发育异常却知之甚少。在本研究中,我们在一组浆细胞发育异常病例中调查了Rb1蛋白表达缺失、Rb1基因重排情况以及p53体细胞突变(第5至9外显子)的存在情况,这些病例包括15例意义未明的单克隆丙种球蛋白病(MGUS)、63例多发性骨髓瘤(MM)和18例浆细胞白血病(PCL)。在同一组病例中,我们确定了与MM相关的主要基因病变——ras癌基因突变的频率。我们报告称,在MM和PCL的原发性病例中,分别有34.7%和9.8%可检测到Rb1蛋白缺失和p53突变;在MGUS中未发现病变。在晚期MM和PCL病例中,检测到了Rb1和p53失活以及ras突变。我们的研究结果表明,Rb1和p53失活与侵袭性浆细胞发育异常有关,提示这些病变在肿瘤进展而非起始过程中起作用。